Sheet 1 of 3

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use coveral sheets if necessary)

ATTY. DOCKET NO. CT2662DIV1 APPLICATION NO. 10/767,645 APPLICANT VRUDHULA ET AL. FILING DATE JANUARY 29, 2004

Group

APR 2 9 2004 S

U.S. PATENT DOCUMENTS

	a THAU				01.100	SUBCLASS	FILING DATE
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME .	CLASS	SUBCLASS	TALKO DATE
	AA					ļ. <u></u>	
	AB						<u> </u>
	AC	·			 _		
	AD						
	AE						ļ
	AF				<u> </u>		

FOREIGN PATENT DOCUMENTS

_			DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	YES	NO NO
-	11.	AG	EP 0 812 831 A1	17 Dec 97	EP				
1//		AH·	EP 0 778 277 A1	11 Jun 97	EP				·
		Al	WO 98/35967	20 Aug 98	PCT				
7		AJ	WO 99/01454	14 Jan 99	PCT				
+		AK	WO 99/10350	04 Mar 99	PCT			ļ	ļ
†		AL	WO 99/67247	29 Dec 99	PCT .				
+	- ;/	AM	WO 00/01675	13 Jan 00	PCT				
+		AN	WO 00/01697	13 Jan 00	PCT				
+		AO	WO 00/39127	06 Jul 00	PCT		·		
+			WO 00/59907	12 Oct 00	PCT				
-ta	K.	AQ	WO 00/59908	12 Oct 00	PCT		<u> </u>		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

twr.	AR	DUNN, et al., "Physiological and behavioral response to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?", Brain Research Reviews, 15, 1990, pp. 71-100
	AS	GULYAS, et al., "Potent, structurally constrained agonists and competitive antagonists of corticotropin- releasing factor," Prac. Natl. Acad. Sci. USA, 92, 1995, pp. 10575-10579
my	AT	McCARTHY, et al., "Recent Advances with the CRF1 Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications," Current Pharmaceutical Design, 5, 1999, pp. 289-315
EXAMINE	R	DATE CONSIDERED 12 2 05

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY, DOCKET NO. CT2662DIV1 APPLICATION NO. 10/767,645 APPLICANT VRUDHULA ET AL. FILING DATE **JANUARY 29, 2004**

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		ONE T	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
70v	TATRA	AA	HOLSBOER, "The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety," Journal of Psychiatric Research, 33, 1999, pp. 181-214
Ī	٦	AB	BANKI, et al., "CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse," European Neuropsychopharmacology, 2, 1992, pp. 107-113
	/	AC	ZOBEL, et al., "Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression, the first 20 patients treated," Journal of Psychiatric Research, 34, 2000, pp. 171-181
	V	,AD	WEBSTER, et al., "Corticotropin-Releasing Hormone and Inflammation," Annals New York Academy of Sciences, 840, 1998, pp. 21-62
	V	AE	GILLIGAN, et al., "Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents," Journal of Medicinal Chemistry, 43, 9, 2000, pp. 1641-1660
7	MV	⁄ĀF	McCARTHY, et al., "Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents," Annual Reports in Medicinal Chemistry, 34, 1999, pp. 11-20
		AG	
		AH	
		AI	
		AJ	
		AK	
		AL	
		АМ	
		AN	
EX/	MINE	R	DATE CONSIDERED 12/2/65

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT2662DIV1 APPLICATION NO. 10/767,645 APPLICANT VRUDHULA ET AL. FILING DATE **JANUARY 29, 2004**

Group

APR 2 9 2004 5

	7			PATENT DOCUMENTS			=0.411	OL ATION
AT & TRADEAN		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	THAN YES	SLATION NO
MICH	W	EP 0 902 029 A1	17 Mar 99	EPO				
1/0/10/1	AΒ	WO 01/007440 A	01 Feb 01	PCT				
1	4C	EP 0 970 958 A	12 Jan 00	EPO		·		
יול זיינה	AD	WO 97/29109 A	14 Aug 97	PCT				
	AE							<u> </u>
/	AF							
1/	AG							
1/	AH		·			·		
- //	Al			·				
	AJ							
	AK							
1	AL							
1	AM							
	AN							
	AO							
- /	AP					·		
	AQ							
-	AR							
	AS							
	ΑŤ							
	AU							
	ΑV							
	AW					·		
	AX							
	AY							
	AZ				·			

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.